z6com时凯集团

Be the most trusted biotech company

2022-04-28

First Subject Dosed in Phase 3 Clinical Trial of Pertuzumab Biosimilar HLX11
2022-04-20

IND Application for Phase 2 Clinical Trial of Serplulimab in Combination with Bevacizumab and Anti-EGFR mAb for the First-Line Treatment of HCC was Approved by The NMPA
2022-04-19

First Patient in Australia Dosed in a Global Multicentre Phase 3 Clinical Study of Henlius Bevacizumab for treatment of Ophthalmic Diseases
2022-04-11

The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for the First-Line Treatment of Small Cell Lung Cancer Accepted by NMPA
2022-04-08

First Patient Dosed in a Global Multicentre Phase 3 Clinical Study of Henlius Bevacizumab for treatment of Ophthalmic Diseases in the EU
2022-04-07

HANSIZHUANG Granted Orphan-Drug Designation in the United States for Small Cell Lung Cancer
2022-03-31

Henlius Anti-PD-1 mAb Serplulimab IND for MRCT Phase 3 Studies on First-Line LS-SCLC Patients Approved by NMPA
2022-03-25

Henlius Receives NMPA Approval for its First Innovative Monoclonal Antibody HANSIZHUANG
2022-03-21

Henlius Published Phase 2 Study Results of Novel anti-PD-1 mAb Serplulimab for the treatment of advanced cervical cancer patients at SGO 2022